The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression
- 57 Downloads
In HER2-positive breast cancer (BC), the standard treatment consists of neoadjuvant sequential chemotherapy, HER2-targeted therapy, surgery, and, if indicated, radiotherapy and/or hormonal therapy. Trastuzumab, a recombinant antibody targeting HER2, has significantly extended the overall survival of BC patients and remains clinically reliable treatment. The 5-year survival, when following the standard treatment protocol, including HER2-targeted therapy, leads to a favorable prognosis with a 5-year survival rate around 75%. Improved overall survival (OS) was reported in BC patients when trastuzumab was administered in both the neoadjuvant and adjuvant period rather than in the adjuvant period alone. Thus, trastuzumab-containing neoadjuvant therapy is currently the standard of care .
A recent study performed by Ignatov et al.  investigated whether the loss of HER2 expression is related to trastuzumab treatment. The cohort consisted of 227 patients, in which second biopsy could be...
Compliance with ethical standards
Conflict of interest
The authors Zuzana Strizova, Jiri Vachtenheim Jr., and Jirina Bartunkova declare that there is no conflict of interest regarding the publication of this article. The manuscript has been approved for publication by all authors and is not currently under review or submitted to another journal.
This article does not contain any studies with human participants or animals performed by any of the authors Zuzana Strizova, Jiri Vachtenheim Jr. and Jirina Bartunkova.
Research involving human and animal participants
Humans were not involved in the study.